{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.0","upperLimit":"30.0","value":"24.0"},{"groupId":"OG001","lowerLimit":"19.0","upperLimit":"32.0","value":"26.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"OS was determined from the date of randomization to the date of death irrespective of the cause of death. Kaplan-Meier estimates were used for analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received either pemetrexed 500 mg/m\\^2 every 21 days until disease progression, unacceptable toxicity or death or docetaxel 75 mg/m\\^2 every 3 weeks until disease progression, unacceptable toxicity or death. Choice of comparator was left to the discretion of the investigator in countries where both treatments are registered to use and are commercially available for second line use (otherwise, docetaxel was administered), assigning the participant to either comparator depending upon the medical needs of the participant. Participants were required to receive concomitant treatment therapy as indicated in the product label.","id":"OG000","title":"Comparator"},{"description":"Participants received erlotinib, 150 mg, administered orally as a tablet, once daily until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Erlotinib"}],"paramType":"NUMBER","populationDescription":"FAS population","reportingStatus":"POSTED","timeFrame":"1 Year","title":"Probable Percentage of Participants Remaining Alive at 1 Year","type":"PRIMARY","unitOfMeasure":"percentage of participants"}